BMJ Masterclass for Physicians: Haematology






Date: Friday 24th May, 2013
Earlybird Deadline: Wednesday 10th April, 2013
Start Time: 9am
End Time: 5pm
Location: BMA House, London
Audience: Consultants, specialty doctors, associate specialist, staff grades, specialist
registrars, trainees (ST1-3), FY1/2
Sessions have been completely revised for 2013 and include plenty of new topics based on your
feedback. Our expert speakers will discuss the latest advances, evidence and guidelines relating to a
wide spectrum of malignant and non-malignant conditions. With interactive sessions, case based
discussions and time to get your questions answered; this Masterclass will provide you with all the
latest information and take home messages to bring your practice up to date.
Why attend:







Earn a minimum of 6 hours CPD credits for your revalidation portfolio or appraisal
Programmes designed by a team of doctors who understand your needs, with a focus on
practical advice.
Fully updated content based on your feedback with take home tips that will help you change
your practice
Get your copy of the essential Haematology course handbook and our ‘track your learning’
document.
Includes a 6 month subscription to BMJ Best Practice
Network with your peers and get your questions answered by our expert speakers
Receive a certificate of attendance as evidence of your learning
“Broad range of subjects, all of which are relevant to everyday haematology work. Very good quality
questions (and answers!).” (Haematology delegate -London, May 2012)
Programme:
Chaired by: Dr Drew Provan
Senior Lecturer in Haematology, Barts and the London School of Medicine and Dentistry, London, and
Editor, ABC of Clinical Haematology
0810
REGISTRATION DESK OPENS
0810–0910
REGISTRATION AND REFRESHMENTS
0910–0920
Welcome and introduction by the Chair
Dr Drew Provan
Senior Lecturer in Haematology, Barts and the London School of Medicine and
Dentistry, London, and Editor, ABC of Clinical Haematology
0920–0955
Investigation of suspected haematological malignancy
In the opening session our speaker will cover the diagnostic approach to patients with
suspected haematological malignancy and the discussion will include:



The way in which complex studies are integrated to produce a final diagnosis
Interactive cases demonstrating the importance of morphology, flow
cytometry, cytogenetics and molecular studies
Common causes of diagnostic error or situations where it is critical to make a
rapid diagnosis.
Dr Christopher McNamara
Consultant Haematologist, The Royal Free Hospital, London
0955-1005
Questions to the speaker
1005-1040
Myeloma
During this session, our expert speaker will provide an overview of multiple myeloma,
including:





Clinical features, staging, and prognosis
Multiple myeloma as of the year 2000: treatments in the conventional
chemotherapy era
Newer developments: the impact of cytogenetics and molecular genetics
The 'novel therapies': thalidomide, lenalidomide, bortezomib – the new
paradigm
Current research questions and the way forward.
Professor Jamie Cavenagh
Clinical Lead in Haemato-Oncology, Barts and the London NHS Trust, London
1040-1050
Questions to the speaker
1050–1110
REFRESHMENTS
1110–1145
Myeloproliferative disorders
This session will focus on the major developments in the myeloproliferative
neoplasms in the last five years, with a particular focus on:



Diagnosis and classification
Pathogenetic and prognostic significance of molecular abnormalities in
chronic and blast-phase disease
Management, including the use of JAK2 inhibitors
Dr Anna Godfrey
Clinical Research Fellow, University of Cambridge and Addenbrooke’s Hospital,
Cambridge
1145–1155
Questions to the speaker
1155–1230
Lymphoma
This session will outline the major advances that have been made in the management
of lymphomas over the past five years, with regard to the development of:




Immunochemotherapy
Prognostic stratification
Response monitoring, particularly with CT and PET scanning.
The speaker will highlight how these advances are making individualised
therapy a realistic prospect.
Professor David Linch
1230–1240
Questions to the speaker
1240–1340
LUNCH
1340–1425
Symposium supported by Pfizer
1425–1500
Haemophilia and von Willebrand disease (vWD)
During this session our speaker will provide an overview of the clinical features and
treatment of haemophilia and vWD. They will also discuss:




Genetics of haemophilia
Management of carriers of haemophilia and the antenatal diagnosis
Acquired haemophilia
Pathophysiology: including the role of vWD in thrombotic thrombocytopenic
purpura
Dr David Keeling
Consultant Haematologist, Oxford Radcliffe Hospitals, Lead Clinician, Oxford
Haemophilia Centre and Thrombosis Unit and Honorary Senior Clinical Lecturer in
Haematology, University of Oxford
1500–1510
Questions to the speaker
1510–1530
REFRESHMENTS
1530–1605
Obstetric haematology
In this session there will be an opportunity for you to learn about current practice in
the management of:




Haematinic deficiencies in pregnancy
Venous thromboembolism (VTE)/ pregnancy loss/ thrombophilia, including
antiphospholipid syndrome (APS)
Obstetric haemorrhage
Pre-eclampsia

Thrombotic thrombocytopenic purpura (TTP) and other microangiopathies.
Professor Beverley Hunt
Professor of Thrombosis & Haemostasis, King's College, Consultant, Departments of
Haematology, Pathology and Lupus, Guy's & St Thomas' NHS Foundation Trust,
London
1605–1615
Questions to the speaker
1615–1650
Transfusion medicine
Although blood transfusion is an essential part of modern medical and surgical
practice, the safety, availability, cost, and clinical indications remain controversial. The
speaker will give an update on:



Current risks of blood component transfusion and the impact of
haemovigilance
Transfusion transmitted variant Creutzfeldt-Jakob disease (vCJD)
Developments in blood component therapy and the emerging evidence base
for clinical practice.
Dr Shubha Allard
Consultant Haematologist, Barts & the London NHS Trust, and NHS Blood &
Transplant and Honorary Clinical Senior Lecturer, Barts and the London School of
Medicine, Queen Mary's University of London, London
1650–1700
Questions to the speaker
1700–1710
Summary and closing remarks
All content has been reviewed by the Chair.
Programme is subject to change.